What's in Daniel Hägi-Pedersen's pipeline?

Daniel Hägi-Pedersen has 2 drugs in our index: 2 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Daniel Hägi-Pedersen's portfolio?

Top competitors by shared drug class: Centre Hospitalier Universitaire de Nice, Helse Nord-Trøndelag HF, Hennepin Healthcare Research Institute, IRCCS Burlo Garofolo, Meshalkin Research Institute of Pathology of Circulation.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/daniel-h-gi-pedersen.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-06-10 · How we verify

Daniel Hägi-Pedersen — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Daniel Hägi-Pedersen pipeline: 2 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Saline isotonic	Saline isotonic	marketed	Crystalloid fluid / Electrolyte solution		Supportive Care / Fluid and Electrolyte Management
Placebo (x4)	Placebo (x4)	marketed

Therapeutic area mix

Supportive Care / Fluid and Electrolyte Management · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Centre Hospitalier Universitaire de Nice · 1 shared drug class
Helse Nord-Trøndelag HF · 1 shared drug class
Hennepin Healthcare Research Institute · 1 shared drug class
IRCCS Burlo Garofolo · 1 shared drug class
Meshalkin Research Institute of Pathology of Circulation · 1 shared drug class
Ministry of Health, Spain · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Daniel Hägi-Pedersen:

Cite this brief

Drug Landscape (2026). Daniel Hägi-Pedersen — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/daniel-h-gi-pedersen. Accessed 2026-06-10.